3750 Cytori Cell Research Institute,Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

3750

TSE Standard

Cytori Cell Research Institute,Inc.

906

JPY

-4

(-0.44%)

Dec 23, 3:30 pm JST

5.78

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	1,388	-731	-745	-831	-101.6	0	May 14, 2021	J-GAAP
Mar, 2022	1,335	-462	-418	-77	-8.8	0	May 13, 2022	J-GAAP
Mar, 2023	2,144	-794	-862	-1,059	-118.7	0	May 12, 2023	J-GAAP
Mar, 2024	1,560	-772	-906	138	15.5	0	May 14, 2024	J-GAAP
Mar, 2025 Guidance	1,284	-84	-87	103	11.5	－	May 14, 2024	J-GAAP
YoY	-17.7%	+89.1%	+90.4%	-25.4%	-25.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 14, 2019	2,800	440	390	380	20	J-GAAP
Results	May 15, 2020	1,180	-129	-185	319	10	J-GAAP
Mar, 2021	May 15, 2020	Available in future release
Results	May 14, 2021
Mar, 2022	May 14, 2021
Results	May 13, 2022
Mar, 2023	May 13, 2022
Results	May 12, 2023
Mar, 2024	May 12, 2023
Results	May 14, 2024
Mar, 2025	May 14, 2024	1,284	-84	-87	103	－	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	8,162	+29.8	Available in future release
Mar, 2001	7,712	-5.5
Mar, 2002	12,306	+59.6
Mar, 2003	9,432	-23.4
Mar, 2004	11,734	+24.4
Mar, 2005	18,298	+55.9
Mar, 2006	22,922	+25.3
Mar, 2007	15,873	-30.8
Mar, 2008	15,640	-1.5
Mar, 2009	17,435	+11.5
Mar, 2010	13,946	-20.0
Mar, 2011	2,535	-81.8
Mar, 2012	2,908	+14.7
Mar, 2013	2,316	-20.4
Mar, 2014	3,531	+52.5
Mar, 2015	4,076	+15.4
Mar, 2016	2,684	-34.2
Mar, 2017	2,692	+0.3
Mar, 2018	522	-80.6
Mar, 2019	1,924	+268.6
Mar, 2020	1,180	-38.7
Mar, 2021	1,388	+17.6
Mar, 2022	1,335	-3.8
Mar, 2023	2,144	+60.6
Mar, 2024	1,560	-27.2
Mar, 2025 Guidance	1,284	-17.7	-84	+89.1	-87	+90.4	11.5	-25.8

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	2,144	-794	-37	-35.64	-7.04	0.14	-118.7
Mar, 2024	1,560	-772	-49	5.50	1.39	0.16	15.5
Mar, 2025 Guidance	1,284	-84	-6.5	4.84	2.00	0.25	11.5

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	22,922	962	1,054	592	517.9
Fiscal Year	Mar, 2006	Mar, 2002	Mar, 2002	Mar, 2019	Mar, 1997

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	667	-203	-181	-43	-4.9	0	May 13, 2022	J-GAAP
Oct - Mar, 2022	972	-414	-425	-498	-55.8	0	May 12, 2023	J-GAAP
Oct - Mar, 2023	698	-418	-483	581	65.1	0	May 14, 2024	J-GAAP
Oct - Mar, 2024 Guidance	1,193	323	332	535	59.9	－	Nov 14, 2024	J-GAAP
YoY	+70.9%	－	－	-7.9%	-8.0%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	-462	-403	-187	-216	35	701	4.38	J-GAAP
Mar, 2023	-794	-322	-39	-283	294	673	4.78	J-GAAP
Mar, 2024	-772	7,537	-1,152	8,689	-7,172	1,038	17.85	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	1,172	-380	-437	-561	-62.9	ー	Nov 11, 2022	J-GAAP
Apr - Sep, 2023	862	-354	-423	-443	-49.7	ー	Nov 10, 2023	J-GAAP
Apr - Sep, 2024	91	-407	-419	-432	-48.4	ー	Nov 14, 2024	J-GAAP
YoY	-89.4%	-15.0%	+0.9%	+2.5%	+2.5%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	479	-135	-164	-161	-18.1	-28.2	Feb 10, 2023	J-GAAP
Jan - Mar, 2023	493	-279	-261	-337	-37.8	-56.6	May 12, 2023	J-GAAP
Apr - Jun, 2023	472	-137	-169	-161	-18.1	-29.0	Aug 10, 2023	J-GAAP
Jul - Sep, 2023	390	-217	-254	-282	-31.6	-55.6	Nov 10, 2023	J-GAAP
Oct - Dec, 2023	549	-140	-172	-109	-12.2	-25.5	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	149	-278	-311	690	77.4	-186.6	May 14, 2024	J-GAAP
Apr - Jun, 2024	39	-239	-233	-242	-27.2	-612.8	Aug 14, 2024	J-GAAP
Jul - Sep, 2024	52	-168	-186	-190	-21.3	-323.1	Nov 14, 2024	J-GAAP
YoY	-86.7%	+22.6%	+26.8%	+32.6%	+32.6%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	485	+370.9	Available in future release
Jan - Mar, 2020	557	+684.5
Apr - Jun, 2020	145	+110.1
Jul - Sep, 2020	383	+455.1
Oct - Dec, 2020	364	-24.9
Jan - Mar, 2021	496	-11.0
Apr - Jun, 2021	461	+217.9
Jul - Sep, 2021	207	-46.0
Oct - Dec, 2021	371	+1.9
Jan - Mar, 2022	296	-40.3
Apr - Jun, 2022	543	+17.8
Jul - Sep, 2022	629	+203.9
Oct - Dec, 2022	479	+29.1
Jan - Mar, 2023	493	+66.6
Apr - Jun, 2023	472	-13.1
Jul - Sep, 2023	390	-38.0
Oct - Dec, 2023	549	+14.6
Jan - Mar, 2024	149	-69.8
Apr - Jun, 2024	39	-91.7
Jul - Sep, 2024	52	-86.7	-168	+22.6	-186	+26.8	-21.3	+32.6

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	7,313	408	421	690	127.2
Fiscal Year	Mar, 2006	Mar, 2005	Sep, 2006	Mar, 2024	Jun, 2010

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	392.12	21.9	16,006	3,501	462	2.65	May 13, 2022	J-GAAP
Mar, 2023	273.41	17.3	14,091	2,441	-596	3.48	May 12, 2023	J-GAAP
Mar, 2024	288.89	44.3	5,816	2,579	-458	0.96	May 14, 2024	J-GAAP
Apr - Sep, 2024	ー	41.3	5,146	2,127	-910	1.12	Nov 14, 2024	J-GAAP

Cytori Cell Research Institute,Inc.(3750) Financial Results